Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
68 hedge funds and large institutions have $554M invested in Akcea Therapeutics Inc in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 18 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
8% less funds holding
Funds holding: 74 → 68 (-6)
16% less call options, than puts
Call options by funds: $7.67M | Put options by funds: $9.18M
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
17% less capital invested
Capital invested by funds: $665M → $554M (-$111M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$64.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.69M |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
+$4.78M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.6M |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$1.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.1M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$2.12M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.29M |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$1.16M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.1M |
AKCA Hedge Fund Activity: Q2 2019 in Review
68 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q2 2019, worth a combined $554M — down 17% from $665M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of AKCA and 15 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 23 added.
The largest buyer was Bellevue Group, adding an estimated $64.1M. The largest seller was Fidelity Investments, cutting an estimated $20.1M.
- 68 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q2 2019, down from 74 in Q1 2019.
- Funds reported $554M of Akcea Therapeutics Inc stock for Q2 2019, down 17% quarter-over-quarter.
- 15 funds opened new Akcea Therapeutics Inc positions in Q2 2019 and 18 closed out, a net change of -3 holders.
- The largest Akcea Therapeutics Inc buyer in Q2 2019 was Bellevue Group, an estimated $64.1M added.
- The largest Akcea Therapeutics Inc seller in Q2 2019 was Fidelity Investments, an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2019.